Valeant To Acquire Sanofi Derma Unit for $425M

Valeant Pharmaceuticals International will acquire Dermik, a dermatology unit of Sanofi in the U.S. and Canada, for approximately $425 million.

Valeant Pharmaceuticals International has signed an agreement to acquire Dermik, a dermatology unit of Sanofi in the U.S. and Canada, for approximately $425 million. The transaction is expected to be accretive in 2011.

The acquisition includes worldwide rights to Sculptra Aesthetic (injectable poly-L-lactic acid) and Sanofi’s Laval, Canada site, a manufacturing facility that currently produces approximately 70 formulations and more than 200 presentations of tablets, capsules, non-sterile liquids, ointments and creams for both Sanofi and third parties. Total 2010 revenues were approximately $240 million. The transaction, subject to certain closing conditions, is expected to be accretive in 2011.

Dermik’s portfolio includes therapeutic and aesthetic dermatology brands such as Ben